Short Interest in CalciMedica Inc. (NASDAQ:CALC) Grows By 91.4%

CalciMedica Inc. (NASDAQ:CALC) saw a significant growth in short interest during the month of June. As of June 15th, there was short interest totaling 276,326 shares, a growth of 91.4% from the May 31st total of 144,356 shares. Based on an average trading volume of 459,271 shares, the days-to-cover ratio is presently 0.6 days. Currently, 3.0% of the company’s shares are short sold.

Insider Activity at CalciMedica

In related news, Director Fred A. Middleton bought 248,972 shares of CalciMedica stock in a transaction that occurred on Thursday, June 25th. The shares were acquired at an average cost of $0.80 per share, for a total transaction of $199,177.60. Following the completion of the acquisition, the director directly owned 1,063,272 shares of the company’s stock, valued at approximately $850,617.60. The trade was a 30.57% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. 41.55% of the stock is currently owned by corporate insiders.

Institutional Trading of CalciMedica

Several hedge funds have recently modified their holdings of CALC. 180 Wealth Advisors LLC boosted its stake in CalciMedica by 297.2% during the first quarter. 180 Wealth Advisors LLC now owns 126,500 shares of the company’s stock worth $68,000 after acquiring an additional 94,650 shares in the last quarter. Boothbay Fund Management LLC bought a new stake in CalciMedica in the fourth quarter valued at $506,000. PVG Asset Management Corp bought a new stake in CalciMedica in the fourth quarter valued at $302,000. Renaissance Technologies LLC raised its holdings in shares of CalciMedica by 45.0% during the first quarter. Renaissance Technologies LLC now owns 128,075 shares of the company’s stock valued at $69,000 after purchasing an additional 39,775 shares during the period. Finally, Envestnet Asset Management Inc. raised its holdings in shares of CalciMedica by 58.2% during the second quarter. Envestnet Asset Management Inc. now owns 93,433 shares of the company’s stock valued at $149,000 after purchasing an additional 34,386 shares during the period.

CalciMedica Trading Up 7.3%

CALC stock traded up $0.07 during mid-day trading on Wednesday, reaching $1.10. The company’s stock had a trading volume of 655,009 shares, compared to its average volume of 1,243,422. The company has a market cap of $17.46 million, a price-to-earnings ratio of -0.84 and a beta of 0.97. The business’s 50 day moving average price is $0.73 and its 200 day moving average price is $1.87. CalciMedica has a 12 month low of $0.46 and a 12 month high of $7.20.

Analyst Upgrades and Downgrades

Separately, Oppenheimer reduced their price objective on shares of CalciMedica from $20.00 to $10.00 and set an “outperform” rating on the stock in a research note on Thursday, March 5th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, CalciMedica currently has an average rating of “Hold” and a consensus price target of $10.00.

CalciMedica Company Profile

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.